Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalysis . These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN102660624A reveals a dual-bacteria catalytic method for high-purity chiral alpha-hydroxy acids, offering significant cost reduction and supply chain reliability for global manufacturers.
Discover advanced biocatalytic synthesis for ticagrelor intermediates using engineered ketoreductase. Achieve high substrate loading and cost reduction in pharmaceutical manufacturing.
Discover the breakthrough SmCR mutant technology for synthesizing optically pure gamma/delta-lactones. Achieve high conversion and purity with our reliable flavor intermediate supply chain solutions.
Patent CN113493814B reveals a one-step enzymatic synthesis of DHEA from androstenedione ester, achieving 94% yield without unstable intermediates.
Patent CN112481224A discloses a robust Baeyer-Villiger monooxygenase for synthesizing high-purity S-benzyl sulfoxide and epsilon-caprolactone with superior stereoselectivity and industrial scalability.
Novel bio-chemical route for phenylephrine ensures high purity and cost efficiency for pharmaceutical supply chains globally via patented enzymatic reduction.
Patent CN117448309A reveals biocatalytic synthesis for high-purity pregabalin intermediates. Achieve significant cost reduction and supply chain reliability.
Novel esterase mutant enables high-yield chiral intermediate production. Reduces cost and improves supply chain reliability for pharmaceutical manufacturing.
Patent CN104651243A reveals a biocatalytic route for (R)-1,3-butanediol. Offers high purity and yield for antibiotic synthesis, ensuring reliable supply chain solutions.
Patent CN109295026B reveals a high-efficiency enzymatic route for Zalcitabine. Discover cost-effective biocatalysis solutions for nucleoside analogues manufacturing.
Patent CN113174377B reveals a stable carbonyl reductase mutant for synthesizing (2R,3S)-MPGM with 100% theoretical yield, offering significant cost reduction in API manufacturing.
Patent CN102719497B details an immobilized yeast method for high-purity methyl (S)-(+)-mandelate. Offers green manufacturing and cost reduction for chiral intermediates.
Patent CN102191293A reveals a novel immobilized yeast method for high-purity duloxetine intermediates, offering significant cost reduction in API manufacturing and scalable supply chain solutions.
Novel biocatalytic route for nicotine intermediate using engineered imine reductase mutants offering superior conversion and stereoselectivity for industrial scale-up.
Patent CN111944774B reveals novel MLADH enzyme for high-purity (R)-PED production. Offers significant cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN103215238B details novel marine esterase PE8 for high-purity pharmaceutical intermediates. Enables cost reduction in API intermediate manufacturing with scalable enzymatic hydrolysis.
Novel stigmasterol based UDCA preparation method ensures high purity and supply chain stability for pharmaceutical intermediates manufacturing processes.
Novel Mycobacterium neoaurum enables high-yield 9-OH AD production with simplified purification for reliable pharmaceutical intermediate supply chains and cost efficiency.
Patent CN103215238A reveals a novel marine esterase PE8 for producing (R)-3-(4-fluorophenyl) monomethyl glutarate, offering a cost-effective enzymatic route for antidepressant intermediates.
Patent CN101392225A reveals a recombinant yeast route for high-purity (S)-CHBE, offering significant cost reduction in API manufacturing and robust supply chain scalability.